Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia chamissonis pollen, also known as Silver Burr Ragweed pollen, is a highly allergenic substance derived from the *Ambrosia chamissonis* plant, a species of ragweed native to the western coastal regions of North America. This wind-borne pollen is a significant cause of seasonal allergic rhinitis (hay fever) and dermatitis in susceptible individuals. Upon inhalation, it triggers an immune response, leading to symptoms such as sneezing, runny nose, itchy eyes, and skin rashes. In some cases, exposure can exacerbate or induce asthma. The allergenic properties are attributed to specific proteins within the pollen grains. As an active ingredient, it is utilized in allergen immunotherapy to desensitize individuals to ragweed pollen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ambrosia chamissonis pollen.